MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Ligand Pharmaceuticals Inc

Cerrado

SectorSalud

124.04 -1.96

Resumen

Variación precio

24h

Actual

Mínimo

121.63

Máximo

126.2

Métricas clave

By Trading Economics

Ingresos

-11M

-42M

Ventas

2.5M

45M

P/B

Media del Sector

47.016

39.564

Margen de beneficio

-93.643

Empleados

68

EBITDA

-11M

-41M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+20.3% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

432M

2.4B

Apertura anterior

126

Cierre anterior

124.04

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

71 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 jul 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 jul 2025, 23:05 UTC

Charlas de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 jul 2025, 20:07 UTC

Ganancias

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 jul 2025, 20:06 UTC

Charlas de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 jul 2025, 19:38 UTC

Charlas de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 jul 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 jul 2025, 19:07 UTC

Charlas de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 jul 2025, 19:03 UTC

Charlas de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 jul 2025, 18:32 UTC

Adquisiciones, fusiones, absorciones

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Adquisiciones, fusiones, absorciones

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 jul 2025, 18:13 UTC

Charlas de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 17:25 UTC

Adquisiciones, fusiones, absorciones

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 jul 2025, 17:24 UTC

Charlas de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 jul 2025, 16:49 UTC

Charlas de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 15:42 UTC

Charlas de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparación entre iguales

Cambio de precio

Ligand Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

20.3% repunte

Estimación a 12 meses

Media 146.4 USD  20.3%

Máximo 157 USD

Mínimo 135 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ligand Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

102.5 / 109.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

71 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.